A*STAR Infectious Diseases Labs (A*STAR IDL)

The infection-causing fungus Candida auris repurposes a calcium pump into a drug export system, allowing its survival against a standard treatment.

A*STAR researchers discover a new vaccine target for malaria that could offer more durable protection.

Researchers pinpoint a specific marker for gastric cancer stem cells and show that eliminating this subpopulation may be a viable approach to more effectively treat stomach cancers.

A molecule found in Aedes mosquito saliva modulates the host body’s immune response during chikungunya infection, highlighting that mosquitoes may be more than just viral carriers.

A*STAR researchers uncover how bacterial hideouts created during tuberculosis infections can also protect and feed other opportunistic invaders.

Region-specific stem cells may not only act as starting points for colorectal cancer, but also offer new clues for early detection and treatment.

As the Chairman of Singapore’s lead R&D public sector agency, Chorh Chuan Tan outlines A*STAR’s strategic role within a new phase of national strategic priorities in research, innovation and enterprise.

A unique RNA structure shared across SARS-CoV-2 variants may contribute to viral fitness, offering a potential target for new antiviral treatments.

An anti-hypertension drug could potentially be repurposed as a more affordable treatment for liver cancer.

Whether combating global viral threats or advancing next-generation telecommunications, the A*STAR winners of the 2025 President’s Science and Technology Awards showcase the talent and drive at the foundations of world-class research excellence.

In recognition of their research excellence, leadership and impact both locally and globally, ten leading A*STAR researchers have been awarded the A*STAR Distinguished Fellowship and Fellowships.

A new ‘liquid lipid’ approach that penetrates the nose’s mucus barrier could lead to needle-free, nasal spray-based mRNA vaccines.